I+ Solutions, Pharmaceutical Import Profile — Mozambique (DGFT 2022–2026)

Name: I+ Solutions, Pharmaceutical Import Records from India — 7 Products, $12.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

I+ Solutions, — Pharmaceutical Importer Profile (2026) | 7 Products, $12.6M Trade | TransData Nexus

I+ Solutions,

Pharmaceutical Importer · Mozambique · Tuberculosis Medications Focus · $12.6M Total Trade · DGFT Verified

I+ Solutions, is a pharmaceutical importer based in Mozambique with a total trade value of $12.6M across 7 products in 3 therapeutic categories. Based on 253 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. I+ Solutions, sources from 1 verified Indian supplier, with Aurigene Pharmaceutical Services Limited accounting for 100.0% of imports.

I+ Solutions, — Import Portfolio & Supplier Network

I+ Solutions, import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to I+ Solutions,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurigene Pharmaceutical Services Limited	$29	5	100.0%

I+ Solutions, sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Aurigene Pharmaceutical Services Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does I+ Solutions, Import?

Formulation	Value	Ships
Apsl-bbi-anti tpo-2, product code: apsl-02563-019, project code	$7	1
Apsl-bbi-anti tpo-1, product code: apsl-02563-016, project code	$6	1
Apsl-bbi-anti tpo-3, product code: apsl-02563-022, project code	$6	1
Apsl-bbi-anti tpo-4, product code: apsl-02563-026, project code	$6	1
Apsl-bbi-anti tpo-5, product code: apsl-02563-029, project code	$4	1

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isoniazid	Tuberculosis Medications	$4.3M	87	0.2%	3
2	Pyrazinamide	Tuberculosis Medications	$2.6M	52	0.3%	3
3	Rifampicin	Advanced Antibiotics	$2.4M	47	0.2%	12
4	Ethambutol	Tuberculosis Medications	$1.2M	24	0.1%	9
5	Linezolid	Advanced Antibiotics	$1.1M	21	1.2%	16
6	Moxifloxacin	Advanced Antibiotics	$733.6K	16	1.2%	9
7	Dolutegravir	Antiviral & HIV Medications	$300.0K	6	0.0%	12

I+ Solutions, imports 7 pharmaceutical products across 3 categories into Mozambique totaling $12.6M.

I+ Solutions, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

I+ Solutions is a pharmaceutical importer and buyer based in Mozambique, specializing in the procurement of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in Mozambique's healthcare sector by ensuring the availability of essential medications, particularly in the treatment of tuberculosis and other infectious diseases. While specific details about its headquarters, parent company, and organizational structure are not publicly disclosed, I+ Solutions is recognized for its significant contributions to the pharmaceutical distribution network within the country.

2Distribution Network

I+ Solutions operates a centralized distribution model, importing pharmaceutical products primarily from India. The company manages a warehouse facility in Maputo, the capital city of Mozambique, which serves as the main hub for storage and distribution. This strategic location enables efficient logistics and timely delivery of medications to various healthcare providers across the country. While the company focuses on domestic distribution, there is no publicly available information indicating operations beyond Mozambique's borders.

3Industry Role

In Mozambique's pharmaceutical supply chain, I+ Solutions functions as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company ensures a steady supply of essential medications to the domestic market. Its focus on importing finished products, rather than raw active pharmaceutical ingredients (APIs), underscores its role in facilitating the availability of ready-to-use medicines for healthcare providers and patients throughout Mozambique.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — I+ Solutions,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

I+ Solutions demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier: Aurigene Pharmaceutical Services Limited. This exclusive sourcing strategy indicates a deep, strategic partnership between I+ Solutions and Aurigene, potentially leading to favorable terms and consistent product quality. However, this single-source dependency also poses risks, such as supply chain disruptions in the event of issues with the supplier. The stability of this relationship is crucial for I+ Solutions' operations, and any changes in the supplier's circumstances could significantly impact the company's ability to meet domestic pharmaceutical demand.

2Supply Chain Resilience

The resilience of I+ Solutions' supply chain is closely tied to its exclusive relationship with Aurigene Pharmaceutical Services Limited. While this partnership may offer benefits like streamlined procurement processes and assured product quality, it also exposes the company to risks associated with single-source dependency. The lack of publicly available information about backup suppliers or alternative sourcing strategies suggests limited diversification in I+ Solutions' supply chain. This concentration could be a strategic choice to maintain close control over product quality and supply consistency. However, it also means that any disruptions affecting Aurigene could have a significant impact on I+ Solutions' ability to supply the Mozambican market.

Importing Pharmaceuticals into Mozambique — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Mozambique

1Regulatory Authority & Framework

The regulation of pharmaceutical products in Mozambique is governed by Law No. 12/2017 of 8th September, which establishes the rules applicable to the production, distribution, use, and marketing of medicines, vaccines, biological products, and health products. This legislation provides a comprehensive framework for ensuring the safety, efficacy, and quality of pharmaceutical products within the country. The Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME) is the national regulatory authority responsible for overseeing the pharmaceutical sector, including the registration and monitoring of pharmaceutical products. ANARME's role is crucial in maintaining the integrity of the pharmaceutical supply chain and protecting public health in Mozambique.

2Import Licensing & GMP

Importers of pharmaceutical products in Mozambique must obtain a license from the Ministry of Industry and Commerce. The licensing process requires compliance with specific conditions, including the recruitment of a qualified technical manager with the necessary qualifications and professional profile approved by the Ministry of Health. Applicants must also demonstrate exclusive dedication to the importation of pharmaceutical products and possess a warehouse that meets safety, security, and storage requirements for medicines. Additionally, importers are required to provide a plan of the establishment, including descriptions and sizes of the areas, and undergo a pre-inspection conducted by the Department of Pharmacy (DoP), which submits an opinion to the Minister of Health. There is a fee payable for a license to export permit of medicines, vaccines, biological, and other health products to importers per the guidelines set forth by the Ministry of Industry and Commerce. (apiex.gov.mz)

I+ Solutions, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

I+ Solutions' product strategy focuses on importing finished pharmaceutical formulations, particularly in the therapeutic areas of tuberculosis medications, advanced antibiotics, and antiviral & HIV medications. This focus aligns with the high demand for these treatments in Mozambique, where infectious diseases are prevalent. The company's import portfolio is heavily concentrated, with the top five products accounting for 91.8% of total imports. This concentration indicates a strategic emphasis on key therapeutic areas to address the most pressing health challenges in the country.

2Sourcing Profile

I+ Solutions employs a sourcing strategy that relies exclusively on a single supplier, Aurigene Pharmaceutical Services Limited, for its pharmaceutical imports. This approach suggests a preference for strong, long-term supplier relationships to ensure product quality and supply consistency. The company's focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a strategy aimed at providing ready-to-use medicines to the Mozambican market. While this sourcing model offers benefits such as streamlined procurement processes, it also introduces risks associated with single-source dependency.

3Market Positioning

Seller's Guide — How to Become a Supplier to I+ Solutions,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter I+ Solutions' supply chain. The company's exclusive sourcing from a single supplier presents an opportunity to diversify its supplier base, thereby enhancing supply chain resilience. Indian exporters can leverage this opportunity by offering competitive pricing, reliable delivery schedules, and high-quality products. By meeting these criteria, new suppliers can position themselves as viable alternatives to I+ Solutions' current supplier, potentially capturing a share of the company's import volume.

2Requirements & Qualifications

Indian exporters seeking to supply I+ Solutions and the broader Mozambican market must adhere to specific certifications, quality standards, and regulatory approvals. Products must be registered with ANARME, Mozambique's national regulatory authority, which requires comprehensive documentation covering quality, safety, efficacy, stability, and manufacturing compliance, including WHO-GMP certification. Additionally, importers must obtain a license from the Ministry of Industry and Commerce, which involves compliance with specific conditions, including the recruitment of a qualified technical manager and possession of a compliant warehouse facility. (apiex.gov.mz)

How to Approach

Frequently Asked Questions — I+ Solutions,

What products does I+ Solutions, import from India?

I+ Solutions, imports 7 pharmaceutical products across 3 categories. Top imports: Isoniazid ($4.3M), Pyrazinamide ($2.6M), Rifampicin ($2.4M), Ethambutol ($1.2M), Linezolid ($1.1M).

Who supplies pharmaceuticals to I+ Solutions, from India?

I+ Solutions, sources from 1 verified Indian suppliers. The primary supplier is Aurigene Pharmaceutical Services Limited (100.0% of imports, $29).

What is I+ Solutions,'s total pharmaceutical import value?

I+ Solutions,'s total pharmaceutical import value from India is $12.6M, based on 253 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does I+ Solutions, focus on?

I+ Solutions, imports across 3 categories. The largest: Tuberculosis Medications (64.8%), Advanced Antibiotics (32.8%), Antiviral & HIV Medications (2.4%).

Get Full I+ Solutions, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.